Company Filing History:
5 out of 445 
2 out of 1,350 
Years Active: 2021-2025
Title: Frederic Tremblay: Innovator in RNAi Technologies
Introduction
Frederic Tremblay is a notable inventor based in Boston, MA, with a focus on innovative RNA interference (RNAi) technologies. He holds a total of six patents, showcasing his contributions to the field of genetic research and therapeutic development. His work has significant implications for treating various disorders associated with specific gene expressions.
Latest Patents
Among his latest patents, Tremblay has developed compositions and methods related to Ketohexokinase (KHK) iRNA agents. This invention involves RNAi agents that target the KHK gene, providing methods to inhibit its expression and potentially treat KHK-associated disorders. Another significant patent focuses on 17ß-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions. This invention includes double-stranded RNA compositions that target the HSD17B13 gene, offering methods to reduce its expression in subjects suffering from related diseases or conditions.
Career Highlights
Frederic Tremblay has worked with prominent companies in the biotechnology sector, including Alnylam Pharmaceuticals, Inc. and Regeneron Pharmaceuticals, Inc. His experience in these organizations has allowed him to contribute to groundbreaking research and development in RNAi technologies.
Collaborations
Throughout his career, Tremblay has collaborated with esteemed colleagues such as James D McIninch and Mark K Schlegel. These partnerships have further enhanced his research capabilities and innovation potential.
Conclusion
Frederic Tremblay's work in RNAi technologies and his six patents reflect his significant contributions to the field of genetic research. His innovative approaches hold promise for advancing therapeutic options for various genetic disorders.